Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.35 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.35 |
| ▸ | BAD | Q92934 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5724877 | 0.99 | MRGPRX4 (0.39) | MRGPRX4MAPTKDM4EMCL1BCL2 | |
| SCHEMBL5725399 | 0.97 | MRGPRX4 (0.41) | MRGPRX4MAPTKDM4EMCL1BCL2 | |
| SCHEMBL5725422 | 0.94 | HPGD (0.38) | MRGPRX4MAPTKDM4EMCL1BCL2 | |
| SCHEMBL13399037 | 0.92 | HPGD (0.41) | MRGPRX4MAPTKDM4EMCL1BCL2 | |
| SCHEMBL5726400 | 0.91 | HPGD (0.39) | MRGPRX4MAPTKDM4EMCL1BCL2 | |
| SCHEMBL5726712 | 0.91 | KDM4E (0.49) | MRGPRX4KDM4ETP53TDP1BDKRB1 | |
| SCHEMBL5724880 | 0.90 | PTGER1 (0.38) | MRGPRX4MAPTKDM4EMCL1BCL2 | |
| SCHEMBL5726387 | 0.88 | SMN1; SMN2 (0.36) | MRGPRX4MCL1BCL2BCL2L1BAD | |
| SCHEMBL5726334 | 0.88 | TP53 (0.41) | MRGPRX4MAPTALDH1A1LMNAPRNP | |
| SCHEMBL13398705 | 0.88 | HPGD (0.42) | MRGPRX4MAPTKDM4EMCL1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6998423-B2 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. (US) | 2006-02-14 | — | — | US | claimed |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC | 2004-09-09 | — | — | US | claimed |
| EP-1448182-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP 2 RECEPTOR SELECTIVE AGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | DUMONT FRANCIS (US) | 2003-09-04 | — | — | US | claimed |
| WO-2003045371-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ADMINISTERING EP2 RECEPTOR SELECTIVE AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-06-05 | — | — | WO | claimed |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLEY Q (US) | 2003-06-05 | — | — | US | claimed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | claimed |
| US-6344485-B1 | Method for treating glaucoma | PFIZER INC. | 2002-02-05 | — | — | US | claimed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | claimed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| EP-0951282-B1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1697356-B1 | PYRIDO[2,3-D]PYRIMIDINE-2,4-DIAMINES AS PDE 2 INHIBITORS | PFIZER PROD INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PFIZER INC. | 2007-06-14 | — | — | US | disclosed |
| EP-0951282-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1999-10-27 | — | — | EP | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027976-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | MRGPRX4 332/4885MAPT 4871/4885KDM4E 3595/4885 |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | MRGPRX4 332/4885MAPT 4871/4885KDM4E 3595/4885 |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | MRGPRX4 332/4885MAPT 4871/4885KDM4E 3595/4885 |
| US-20070135457-A1 | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde2 inhibitors | PDE12, PDE2A, PDE3A | MRGPRX4 1569/4885MAPT 2891/4885KDM4E 1063/4885 |
| US-20030166631-A1 | Pharmaceutical compositions and methods for administering EP2 receptor selective agonists | PTGER2, PTGER1, PTGFR | MRGPRX4 194/4885MAPT 4847/4885KDM4E 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.